CIPLA2024-04-012024-06-30 CIPLA2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member CIPLA2024-06-30 CIPLA2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue01Member CIPLA2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue02Member CIPLA2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults01Member CIPLA2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults02Member CIPLA2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets01Member CIPLA2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets02Member CIPLA2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities01Member CIPLA2024-06-30in-bse-fin:OneReportableSegmentLiabilities01Member CIPLA2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities02Member CIPLA2024-06-30in-bse-fin:OneReportableSegmentLiabilities02Member CIPLA2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member CIPLA2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500087 CIPLA NOTLISTED Cipla Limited Equity 2024-04-01 2025-03-31 2024-07-26 2024-07-04 INR Crores First quarter 11:15:00 15:40:00 2024-07-26 2024-07-26 Not applicable Multi segment 2024-04-01 2024-06-30 Unaudited Consolidated 66939400000.00 1601900000.00 68541300000.00 12409000000.00 10999900000.00 -1480100000.00 11942300000.00 179500000.00 2466800000.00 15910300000.00 52427700000.00 16113600000.00 0.00 16113600000.00 4312700000.00 38000000.00 4350700000.00 0.00 11762900000.00 0.00 0.00 0.00 -8300000.00 11754600000.00 707400000.00 12462000000.00 11776400000.00 -21800000.00 12485800000.00 -23800000.00 1615000000.00 2 14.58 14.57 0.00 0.00 14.58 14.57 0.00 0.00 0.00 Since the characters in the notes exceed the set limit, it is requested to refer to the detailed notes in PDF result as uploaded on the Stock Exchanges. Other Expenses 15910300000.00 New ventures 3539800000.00 Pharmaceuticals 63893000000.00 67432800000.00 493400000.00 66939400000.00 New ventures -13300000.00 Pharmaceuticals 16306400000.00 16293100000.00 179500000.00 Segment assets and liabilities As certain assets and liabilities are deployed interchangeably across segments, it is not practically possible to allocate those assets and liabilities to each segment. Hence, the details of assets and liabilities have not been disclosed in the above table. 16113600000.00 New ventures 0.00 Pharmaceuticals 0.00 0.00 New ventures 0.00 Pharmaceuticals 0.00 0.00 Items that will not be reclassified to profit or loss -62400000.00 -62400000.00 -15000000.00 Items that will be reclassified to profit or loss 724300000.00 724300000.00 -30500000.00